Report data from the AK006 Phase 1 CSU patient cohort
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 17 Jan 2024
- Due
- 31 Mar 2025
- Delivered
- 27 Jan 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Part C: CSU Patients Data Availability (n=30)”
What we found
Evidence strength A What the grades mean
Allakos reported topline Phase 1 CSU patient cohort data (n=34) on January 27, 2025, within the Q1 2025 deadline.
-
A Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria SEC filing with full topline results announcement for CSU cohort with 34 patients
-
B Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria Company press release announcing CSU cohort data results and safety profile
Checked 21 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Allakos Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-C564824-000023 · Corrections policy